Transcriptional signatures associated with rubella virus‐specific humoral immunity after a third dose of MMR vaccine in women of childbearing age

Haralambieva, Iana H.; Eberhard, Katherine G.; Ovsyannikova, Inna G.; Grill, Diane E.; Schaid, Daniel J.; Kennedy, Richard B.

doi:10.1002/eji.202049054

Cited by 4 publications

(2 citation statements)

References 86 publications

(125 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The following methods are similar or identical to our previously published studies [16][17][18][19][20].…”

Section: Methodsmentioning

confidence: 99%

“…mRNA next-generation sequencing was performed using similar protocols, as described in our previous publications [16,18,22]. Briefly, untouched CD4 + Tcells were first isolated from PBMCs via negative selection (depletion of non-target cells expressing CD8, CD14, CD15, CD16, CD19, CD34, CD36, CD56, CD123, and CD235a), using the Miltenyi Biotec's Pan-T cell isolation kit, CD8 specific magnetic microbeads, LS columns, and a MidiMACS™ Separator.…”

Section: Mrna Sequencingmentioning

confidence: 99%

See 1 more Smart Citation

T Cell Transcriptional Signatures of Influenza A/H3N2 Antibody Response to High Dose Influenza and Adjuvanted Influenza Vaccine in Older Adults

Haralambieva

Quach

Ovsyannikova

et al. 2022

Viruses

Self Cite

View full text Add to dashboard Cite

Older adults experience declining influenza vaccine-induced immunity and are at higher risk of influenza and its complications. For this reason, high dose (e.g., Fluzone) and adjuvanted (e.g., Fluad) vaccines are preferentially recommended for people age 65 years and older. However, T cell transcriptional activity shaping the humoral immune responses to Fluzone and Fluad vaccines in older adults is still poorly understood. We designed a study of 234 older adults (≥65 years old) who were randomly allocated to receive Fluzone or Fluad vaccine and provided blood samples at baseline and at Day 28 after immunization. We measured the humoral immune responses (hemagglutination inhibition/HAI antibody titer) to influenza A/H3N2 and performed mRNA-Seq transcriptional profiling in purified CD4+ T cells, in order to identify T cell signatures that might explain differences in humoral immune response by vaccine type. Given the large differences in formulation (higher antigen dose vs adjuvant), our hypothesis was that each vaccine elicited a distinct transcriptomic response after vaccination. Thus, the main focus of our study was to identify the differential gene expression influencing the antibody titer in the two vaccine groups. Our analyses identified three differentially expressed, functionally linked genes/proteins in CD4+ T cells: the calcium/calmodulin dependent serine/threonine kinase IV (CaMKIV); its regulator the TMEM38B/transmembrane protein 38B, involved in maintenance of intracellular Ca2+ release; and the transcriptional coactivator CBP/CREB binding protein, as regulators of transcriptional activity/function in CD4+ T cells that impact differences in immune response by vaccine type. Significantly enriched T cell-specific pathways/biological processes were also identified that point to the importance of genes/proteins involved in Th1/Th2 cell differentiation, IL-17 signaling, calcium signaling, Notch signaling, MAPK signaling, and regulation of TRP cation Ca2+ channels in humoral immunity after influenza vaccination. In summary, we identified the genes/proteins and pathways essential for cell activation and function in CD4+ T cells that are associated with differences in influenza vaccine-induced humoral immunity by vaccine type. These findings provide an additional mechanistic perspective for achieving protective immunity in older adults.

show abstract

“…The following methods are similar or identical to our previously published studies [16][17][18][19][20].…”

Section: Methodsmentioning

confidence: 99%

Section: Mrna Sequencingmentioning

confidence: 99%